Primary Extra-Osseous Ewing Sarcoma of the Thyroid: A Case Report and Review of the Literature

Amanda H. Seipel1 · Hiba Mechahougui2 · Nicolas Mach2 · Frédéric Triponez3 · William C. Faquin4 · Claudio De Vito1

Received: 2 June 2021 / Accepted: 14 July 2021 / Published online: 26 July 2021
© The Author(s) 2021

Abstract
Extra-osseous Ewing sarcoma (ES) is a rare and aggressive malignant tumor found in a variety of organs. Primary ES of the thyroid is exceedingly rare and few cases have been documented to date. We describe the case of a 54-year-old woman with a history of breast carcinoma in whom a unique hypermetabolic left thyroid nodule was identified during a follow-up PET-CT scan. An ultrasound examination showed a hypoechogenic nodule of 3.7 cm. A cytological diagnosis of poorly differentiated thyroid carcinoma was made, and a total thyroidectomy was performed. The surgical specimen revealed a poorly differentiated neoplasm composed of medium-sized cells with scant cytoplasm, expressing pancytokeratin, CD99 and NKX2.2 but lacking p63 and p40 expression. Molecular analysis revealed an EWSR1-FLI1 fusion transcript supporting the diagnosis of a primary extra-osseous ES of the thyroid. The patient received adjuvant chemotherapy and has no evidence of recurrent disease.

Keywords Thyroid gland · Extra-osseous Ewing sarcoma · Cyto-histological correlation · Molecular analysis

Introduction
Thyroid cancers encompass a wide range of tumors, from indolent cases with low mortality to extremely aggressive malignancies with short overall survival. Proper diagnostic work-up and classification are crucial to tailor patient treatment. Well-differentiated thyroid carcinoma such as papillary, follicular and Hürthle cell carcinoma account for more than 95% of all cases, while other subtypes are less frequently seen [1]. Mesenchymal thyroid neoplasms are exceedingly rare among which Ewing sarcoma (ES) represents only 2% [2]. ES is a member of the so-called “small round blue cell” tumors, most commonly arising in bone and most frequently found in children and adolescents. Extra-osseous Ewing sarcoma (EES) is less frequent and can occur at a wide variety of anatomic [3]. Several recent reports have described an adamantinoma-like Ewing sarcoma (ALES) arising in the thyroid gland, based on the identification of EWSR1 rearrangement in neoplasms showing the classic ES morphology with epithelial differentiation (keratin and p63 or p40 expression) [4–8], and carcinoma of the thyroid with Ewing family tumor elements (CEFTEs) when associated with papillary thyroid carcinoma [9–12]. Here we present the case of a patient diagnosed with EES located in the left thyroid lobe and a review of the current literature.

Case

Clinical History
A 54-year-old woman presented with a 3.7 cm nodule in the left thyroid lobe during a routine PET-scan follow-up for a triple negative breast carcinoma, without BRCA-1 or BRCA-2 mutation, treated with neoadjuvant chemotherapy, surgery, and radiotherapy. Physical examination revealed an asymmetric thyroid gland with a firm nodule of the left thyroid lobe, without any palpable lymphadenopathy.
Ultrasound imaging revealed a hypoechogenic and hypervascularized nodule measuring 3.7 × 3.1 × 2.1 cm without calcifications which was classified radiologically as TI-RADS 4.

An US-guided fine needle aspiration (FNA) was performed which showed a monomorphic proliferation of dyscohesive cells isolated and in groups, with scant cytoplasm and distinct small nucleoli (Fig. 1A). The cells stained diffusely for pancytokeratin (Fig. 1B), and scattered cells stained for TTF-1 (Fig. 1C) and thyroglobulin (data not shown). GATA-3, calcitonin, mammaglobin, estrogen and progesterone receptors were negative (data not shown). Based on the cytomorphology and immunocytochemical profile a diagnosis of poorly differentiated thyroid carcinoma (PDTC) was made, and the patient underwent a total thyroidectomy.

The surgical specimen of the left thyroid lobe showed a poorly delineated cream-colored nodule with hemorrhagic zones, measuring 4 cm, occupying the superior and medial part of the thyroid, which was extensively sampled. The right lobe contained a small, sclerotic nodule.

Histological analysis showed a solid cellular proliferation separated by fibrous bands, composed of small to medium sized cells with scant cytoplasm and an enlarged nucleus. Chromatin was evenly distributed and nucleoli were inconspicuous (Fig. 2A). Mitoses were scarce. Multifocal vascular invasion was observed, without any evidence of lymphatic or perineural invasion. The tumor was limited to the thyroid gland but focally in contact with the surgical margins. Immunohistochemistry showed diffuse expression for pancytokeratin, epithelial membrane antigen (EMA), CD117, CD99 (Fig. 2B) and NKX2.2. The cells were negative for PAX-8, thyroglobulin, CEA, calcitonin, p63, p40 (Fig. 2C), chromogranin, synaptophysin, hormonal receptors (ER, PR), GATA3, mammaglobin and BRST2. P53 showed a wild type expression. INI-1 and BRG-1 expression was conserved. Scattered non-neoplastic thyrocytes expressing TTF-1 were observed entrapped within the tumor. The surrounding thyroid parenchyma showed mild chronic thyroiditis.

Based on the histomorphology and immunohistochemical profile, an RNA-based fusion panel (Illumina TruSight Fusion panel, Illumina, San Diego, CA) was performed and identified an EWSR1-FLI1 fusion transcript, validated by a EWSR1 FISH break apart probe (Fig. 2D) supporting the diagnosis of EES. An additional custom NGS targeted panel (including more than 400 genes) did not identify any gene mutation. Since PET/CT did not reveal involvement of other anatomic sites, a diagnosis a primary EES of the thyroid gland was made. Based upon the overall pathologic and clinical findings, the multidisciplinary institutional tumor board panel recommended adjuvant chemotherapy.

The patient then received four cycles of adjuvant polychemotherapy with VIDE (Vincristine, Ifosfamide, Doxorubicin, Etoposide) and Peg G-CSF.

Adequate cardiac function was confirmed by cardiac ultrasound as part of the pre-treatment protocol and because the patient had already received 360 mg/m² of Epirubicin in 2016 for the multimodality treatment of a triple negative breast cancer. Chemotherapy was complicated by grade 3 asthenia, and grade 4 neutropenia, anemia, and thrombocytopenia requiring a 20% dose reduction for the last two
cycles. Treatment was completed with adjuvant radiotherapy (total dose 45 Gy delivered in 25 sessions). As this patient presented with two rare and aggressive neoplasms, triple negative breast cancers and a sarcoma developed within the field of her breast cancer radiotherapy, genetic predisposition such as Li-Fraumeni syndrome was suspected. Genetic analysis of eight genes: TP53, PTEN, STK11, PALB2, ATM, CHEK 2, did not reveal any anomaly.

Fifteen months after surgery, the patient is in remission with no local recurrence no distant metastases.

Discussion

Primary ES family tumors tend to occur most commonly in bone, primarily in adolescents and young adults, and is characterized by chromosomal rearrangements involving the EWSR1 gene [3]. More recently EES termed ALES has been increasingly recognized in the head and neck region including salivary gland and thyroid [13], and also carcinoma of the thyroid with CEFTEs [9]. Although ES can express epithelial markers such as pankeratin [14], p63 and/or p40 were reported only in ALES [13]. In our case, the absence of p40 and p63 expression and the lack of papillary thyroid carcinoma foci associated with the tumor support the classification of EES over ALES or CEFTE.

It is interesting to note that the few cases that were able to correctly diagnose the tumor were done in association with a core needle biopsy [15, 16] or excision biopsy [4] (Table 1).

As in our case, a potential pitfall in the interpretation of cytological specimens is the diffuse expression of keratin, which may lead to the misclassification of the cancer as PDTC. This is especially true when entrapped benign, TTF-1 positive thyrocytes are present in the FNA sample as encountered in our case, and similarly as described by Chikeka et al. [17], or when p40 or p63 are only expressed focally [6, 8], or are absent.

The differential diagnosis encompasses a broad range of neoplasms including metastatic basaloid squamous cell carcinoma, which expresses keratin, p63 and p40, and medullary thyroid carcinoma which can be confirmed by testing for calcitonin and CEA expression. In the setting of a calcitonin-negative tumor, other neuroendocrine entities of the thyroid gland including intrathyroidal paraganglioma should be considered. Intrathyroidal thymic carcinoma based on the immunohistochemical profile (positivity for keratin, EMA and CD117) should also be excluded.

Given the high-grade nature of the tumor and unusual immunoprofile and histomorphology, a thyroid gland metastasis should also be considered. In our case, a metastasis from the patient’s known breast cancer was excluded using immunohistochemical markers for GATA-3, mammaglobin, and BRST2. This clinical presentation of EES is reminiscent of the case reported by Maldi et al. [6].

ES is an aggressive disease with a 70% overall 5-year relative survival rate [3]. However, the difference in...
| Age | Sex | FNA/core needle biopsy | Tumor size | Adverse factor | Treatment | Follow up/outcome | p40/p63 expression | other |
|-----|-----|------------------------|------------|----------------|-----------|------------------|--------------------|-------|
| 9   | F   | Ewing sarcoma          | 6.0 cm     | Lymph node metastasis | Chemotherapy, surgery, radiotherapy | 6 years, ANED | N/A |
| 42  | F   | Follicular tumor       | 2.5 cm     | Vascular invasion  | Total thyroidectomy | 38 months, ANED | Positive CEFTE |
| 66  | M   | Malignant tumor of possible neuroectodermal origin | 4.5 cm | Vascular invasion | Total thyroidectomy, no chemotherapy or radiotherapy | 8 months/ AWED | Focal expression |
| 48  | M   | Giant B-cell non-Hodgkin lymphoma | 10 cm | Positive surgical margins | CHOP (initial diagnosis of B cell non Hodgkin lymphoma), followed by etoposide and carboplatin | 1 month, died from brain metastasis | N/A |
| 23  | M   | Not performed          | 4.7 cm     | Vascular invasion, lymph node metastasis | Total thyroidectomy (2 steps), chemotherapy under chemotherapy | N/A |
| 67  | F   | Bethesda IV            | 4.0 cm     | Vascular invasion  | Total thyroidectomy (2 steps), radioactive iodine | 22 months ANED | N/A |
| 24  | M   | Not performed          | 5.3 cm     | Vascular invasion  | Total thyroidectomy (2 steps), radiotherapy | 13 years/ ANED | Positive CEFTE |
| 19  | M   | N/A                    | N/A        | N/A              | Surgery, additional therapy pending | 0 month | Focally positive (<5%) |
| 36  | F   | N/A                    | N/A        | N/A              | Surgery, additional therapy pending | 0 month | Positive |
| 34  | M   | Small-cell malignant neoplasm, most likely of hematologic origin/ core needle bx: ewing sarcoma | 6.0 cm | Not reported | Neo-adj. chemotherapy ishmolobectomy, cervical lymphadenectomy, radiotherapy (discontinued) | 18 months | N/A |
| 36  | M   | Suggestive of malignancy | 7.0 cm     | Extrathyroidal extension, lymphovascular invasion, lymph node metastases | Total thyroidectomy, medial and right lateral neck dissection, chemotherapy | 2 years, ANED pancreatic metastasis treated by chemotherapy | N/A |
| 20  | F   | Suspicious for carcinoma | 4.0 cm     | Not reported | Total thyroidectomy, chemotherapy, radiotherapy | 7 months ANED | Positive |
prognosis between EES and ES is still controversial. A report from the Children’s Oncology Group analyzing a cohort of two clinical trials including 213 extraskeletal ES and 826 skeletal ES showed that EES were associated with a slightly better event-free survival [18]. In contrast, Lynch et al. [19] did not find any impact on survival in the adult population. Most patients with thyroid involvement presented with angio-lymphatic invasion and a small subset with lymph node metastasis (Table 1). The majority of patients received adjuvant chemotherapy and all showed no evidence of disease in the clinical follow-up except for one patient [20]. However, it is important to emphasize that the clinical follow-up for most patients was limited, and therefore any conclusions about the long term patient prognosis is uncertain.

In conclusion, correct pre-operative diagnosis of extraskeletal ES remains challenging. Pathologists, including those specializing in cytopathology, should be aware that ES should be considered in the differential diagnosis of poorly differentiated tumors of the thyroid, including those with diffuse keratin expression and focal expression of p40/p63. For such cases, CD99 and NKX2.2 immunostaining or molecular analysis with NGS or FISH can be helpful to properly classify the tumor which is of crucial importance for proper patient management.

Authors contribution AHS and CDV wrote the manuscript. AHS, CDV and WCF provided the pathological pictures, HM, NM and FT provided clinical information, CDV supervised the manuscript. All the authors reviewed and edited the manuscript.

Funding Open Access funding provided by Université de Genève. No funds, grants, or other support was received.

Data and material availability Not applicable.

Code availability Not applicable.

Declarations

Conflict of interest The authors declare that there is no conflict of interest.

Ethics Approval Not required.

Consent to Participate Not applicable.

Consent for Publication Written consent from the patient.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated

Table 1 (continued)

| Age | Sex | FNA/needle biopsy | Tumor size | Adverse factor | Treatment | Follow up/outcome | p40/p63 expression | Other |
|-----|-----|-------------------|------------|----------------|-----------|------------------|-------------------|-------|
| 21 M | M (transgender) | ALES | 7.0 cm | N/A | N/A | N/A (numerous lytic bone lesions) | Positive | CEFTE |
| 15 F | Bethesda VI | Bethesda V | 3.0 cm | N/A | Positive surgical margins | Total thyroidectomy, chemotherapy, radiotherapy | 6 months ANED | Positive |
| 40 M | Bethesda V | Bethesda VI | 6.5 cm | Not reported | Vascular invasion, positive surgical margins | Total thyroidectomy, chemotherapy, radiotherapy | 15 months ANED | Negative |
| 54 F | Bethesda V | Bethesda VI | 4.0 cm | N/A | Positive surgical margins | Total thyroidectomy, chemotherapy, radiotherapy | N/A | Positive |
| Jones and Maleki [16] | | | | | | | | |
| Chikeka et al. [17] | | | | | | | | |
| Taccogna et al. [10] | | | | | | | | |
| Current case | | | | | | | | |

AWED alive, no evidence of disease, ANED alive with evidence of disease, N0I not available, CEFTE adamantinoma-like Ewing sarcoma.
References

1. Haddad RI, Nasr C, Bischoff L, et al. NCCN Guidelines insights: thyroid carcinoma, version 2.2018. J Natl Compr Canc Netw. 2018;16:1429–40.
2. Gubbi S, Thakur S, Avadhanula S, et al. Comprehensive guidance on the diagnosis and management of primary mesenchymal tumours of the thyroid gland. Lancet Oncol. 2020;21:e528–37.
3. Riggi N, Suvà ML, Stamenkovic I. Ewing’s sarcoma. N Engl J Med. 2021;384:154–64.
4. Adapa P, Chung T-W, Popek EJ, Hunter JV. Extraosseous Ewing sarcoma of the thyroid gland. Pediatr Radiol. 2009;39:1365–8.
5. Chan JM, Bilodeau E, Celin S, et al. Ewing sarcoma of the thyroid: report of 2 cases and review of the literature. Head Neck. 2013;35:E346–50.
6. Maldi E, Monga G, Rossi D, et al. Extra-osseous Ewing sarcoma of the thyroid gland mimicking lymphoma recurrence: a case report. Pathol Res Pract. 2012;208:356–9.
7. Chirila M, Muresan M, Ciuleanu E, Cosgarea M. Extraosseous Ewing sarcoma and peripheral primitive neuroectodermal tumor of the thyroid gland: case report and review. Ear Nose Throat J. 2013;92:E3-6.
8. Bishop JA, Alaggio R, Zhang L, et al. Adamantinoma-like Ewing family tumors of the head and neck: a pitfall in the differential diagnosis of basaloid and myoepithelial carcinomas. Am J Surg Pathol. 2015;39:1267–74.
9. Oliveira G, Polônia A, Cameselle-Teijeiro JM, et al. EWSR1 rearrangement is a frequent event in papillary thyroid carcinoma and in carcinoma of the thyroid with Ewing family tumor elements (CEFT). Virchows Arch. 2017;470:517–25.
10. Taccogna S, Guglielmi R, Persichetti A, et al. Carcinomas of the thyroid with Ewing family tumor elements (CEFTes): a diagnostic challenge before surgery. Head Neck Pathol. 2021;15:254–61.
11. Eloy C, Oliveira M, Vieira J, et al. Carcinoma of the thyroid with Ewing family tumor elements and favorable prognosis: report of a second case. Int J Surg Pathol. 2014;22:260–5.
12. Eloy C, Cameselle-Teijeiro J, Vieira J, et al. Carcinoma of the thyroid with Ewing/PNET family tumor elements: a tumor of unknown histogenesis. Int J Surg Pathol. 2014;22:579–81.
13. Rooper LM, Bishop JA. Soft tissue special issue: adamantinoma-like Ewing sarcoma of the head and neck: a practical review of a challenging emerging entity. Head Neck Pathol. 2020;14:59–69.
14. Srivastava A, Rosenberg AE, Selig M, et al. Keratin-positive Ewing’s sarcoma: an ultrastructural study of 12 cases. Int J Surg Pathol. 2005;13:43–50.
15. Kabata P, Kaniuka-Jakubowska S, Kabata W, et al. Primary Ewing sarcoma of the thyroid-eight cases in a decade: a case report and literature review. Front Endocrinol (Lausanne). 2017;8:257.
16. Jones R, Maleki Z. Adamantinoma-like Ewing sarcoma of the thyroid. Diagn Cytopathol. 2020;48:E4–6.
17. Chikeka I, Sung S, Tiscornia-Wasserman P, Cimic A. Adamantinoma-like Ewing sarcoma of the thyroid gland: cytomorphologic, phenotypic and molecular features. Diagn Cytopathol. 2020;48:1107–10.
18. Cash T, McIlvaine E, Kralio MD, et al. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2016;63:1771–9.
19. Lynch AD, Gani F, Meyer CF, et al. Extraskeletal versus skeletal Ewing sarcoma in the adult population: controversies in care. Surg Oncol. 2018;27:373–9.
20. Ongkeko M, Zeck I, de Brito P. Molecular testing uncovers an adamantinoma-like Ewing family of tumors in the thyroid: case report and review of literature. AJSP Rev Rep. 2018;23:8–12.
21. Morlote A, Harada S, Lindeman B, Stevens SM. Adamantinoma-like Ewing sarcoma of thyroid: a case report and review of the literature. Head Neck Pathol. 2019;13:618–23.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.